StockData
Elanco Animal Health Inc logo

Elanco Animal Health Inc (ELAN) company profile

ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$25.85−0.56 (-2.12%)

Close on Nov 17, 2026Market cap $12.92BP/E –Yield –

About Elanco Animal Health

Pharmaceutical Preparations, SIC 2834

Elanco Animal Health Incorporated develops, manufactures, and markets products to prevent and treat disease in pets and farm animals. Operating as a single segment within the animal health industry, the company provides treatments primarily for dogs, cats, cattle, poultry, swine, and sheep. Its product line encompasses parasiticides, dermatology treatments, vaccines, pain management therapeutics, medicated feed additives, injectable antibiotics, and enzymes. Elanco distributes its pet care offerings to third-party distributors, retailers, and veterinary clinics, while its farm animal products are supplied to commercial distributors and livestock producers.

The company sells its portfolio across more than 90 countries, with the United States representing its largest market alongside key international markets in Brazil, the United Kingdom, and China. Global commercial operations are supported by 16 manufacturing facilities situated across eight countries, as well as an extensive network of contract manufacturing organizations and international research and development sites. Elanco maintains its research and development headquarters in Indianapolis, Indiana.

Summary of the business section of Elanco Animal Health's latest annual report, written by StockData.

Company profile

Company

Legal name
Elanco Animal Health Inc
Founded
1954
Headquarters
Indianapolis, IN
Address
450 Elanco Circle 46221
Phone
(877) 352-6261
Employees
9,400, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Indianapolis, Indiana

Stock & identifiers

Ticker
ELAN
Exchange
NYSE
IPO date
Sep 21, 2018
Shares outstanding
500M, Aug 3, 2026
Public float
$7.00B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1739104
CUSIP
28414H103
ISIN
US28414H1032
FIGI
BBG00LJYS1P8
Share class FIGI
BBG00LJYS1R6
LEI
549300SHPNDCE059M934
EIN
82-5497352

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeffrey N. SimmonsPRESIDENT, CEO AND DIRECTOR2,223,869
Robert M. VanHimbergenEVP and CFO137,516
Rajeev A. ModiSEE REMARKS160,812
Jamie PrestonEVP, Chief People Officer–
Timothy J. BettingtonSEE REMARKS138,911
Shiv O'NeillGC AND CORP SEC87,832
David S. KinardSEE REMARKS214,264
Brabander Ellen deSEE REMARKS280,821
de Simas Jose Manuel CorreiaSEE REMARKS101,017
Grace McArdleEVP, MANUFACTURING AND QUALITY103,705
Ramiro Martin CabralSEE REMARKS283,874
James M. MeerCHIEF ACCOUNTING OFFICER66,732
Todd S. YoungSEE REMARKS369,839
Kapila K. AnandDirector111,847
Lawrence Erik KurziusDirector188,647
Michael J. HarringtonDirector131,451
Paul HerendeenDirector111,687
Deborah Turner KochevarDirector94,392
Denise Scots-KnightDirector93,392
R. David HooverDirector277,371
Art A. GarciaDirector108,152
Kirk P. McDonaldDirector105,588
Stacey MaDirector17,531
Kathy V. TurnerDirector13,838
Craig S. WallaceDirector13,838

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$14.93M$37.81M$3.83M$74$188
FY2024$14.83M$9.23M$3.37M$39$148
FY2023$13.66M$17.32M$3.03M$49$137
FY2022$12.71M-$2.02M$2.78M$40$136
FY2021$12.06M$16.53M$3.20M$93$126
FY2020$8.96M$9.32M$2.15M$104$108

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jeffrey Simmons
President and CEO
$1.20M–$9.00M$3.00M$1.70M$25.35K$14.93M+1%
Robert VanHimbergen
Executive Vice President and Chief Financial Officer
$317.31K$890.00K$2.29M$550.00K$539.55K$79.42K$4.66M–
Ellen de Brabander
Executive Vice President, Innovation and Regulatory
$847.83K–$1.72M$572.00K$739.31K$36.08K$3.91M-0%
Ramiro Cabral
Executive Vice President, President International
$650.00K–$1.50M$500.00K$566.80K$26.95K$3.24M+10%
Timothy Bettington
Executive Vice President, Center for Strategic Growth
$656.00K–$1.05M$350.01K$500.53K$26.95K$2.58M+2%
Todd Young
Former Executive Vice President and Chief Financial Officer
$477.10K–$2.18M$725.00K–$1.38M$4.75M+16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 21, 2018
Offer price
$24.00
Securities offered
62,900,000
Gross proceeds
$1.51B
Exchange
NYSE
Lock-up ends (est.)
Mar 20, 2019

“The initial public offering price per share is $24.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed approximately 9,400 full time employees and approximately 500 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).”

Corporate history

Events identified from SEC filings

See a number that looks wrong?